PD-1 blockade induces responses by inhibiting adaptive immune resistance¶
Why this mattered¶
Tumeh et al. mattered because it gave a tissue-level mechanism for why PD-1 blockade could produce dramatic melanoma regressions in some patients but not others. The paper showed that response to pembrolizumab was associated with a pre-existing antitumor immune reaction: CD8+ T cells concentrated at the invasive tumor margin, nearby PD-1/PD-L1 expression, and a more clonal T-cell receptor repertoire. After treatment, responding tumors showed proliferating intratumoral CD8+ T cells whose increase tracked with radiographic tumor shrinkage. This shifted PD-1 therapy from a black-box clinical phenomenon to a model of releasing an already-engaged, locally inhibited immune response.
The paradigm change was subtle but durable: successful checkpoint blockade was not simply “stimulating immunity” in general, but disabling an adaptive resistance circuit used by tumors under immune pressure. That idea made new forms of prediction and trial design possible. Tumors could be studied as spatial immune ecosystems, where the location, state, and clonality of T cells mattered alongside tumor genetics. It also clarified why PD-L1 alone was an incomplete biomarker: the relevant biology was the coordinated presence of antigen-experienced T cells, inhibitory ligand expression, and tumor-immune contact.
Subsequent immuno-oncology built heavily on this framework. The “hot” versus “cold” tumor distinction, spatial profiling of the tumor microenvironment, T-cell-inflamed gene signatures, and combination strategies aimed at recruiting or reinvigorating T cells all trace back to the same logic. Later breakthroughs in checkpoint combinations, neoadjuvant immunotherapy, adaptive-resistance mapping, and single-cell/spatial immune atlases extended the paper’s central claim: durable cancer immunotherapy depends on understanding not only whether immune cells are present, but whether their local restraints can be released.
Abstract¶
(no abstract available)
Related¶
- cite → Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer — The adaptive immune resistance paper builds on anti-PD-L1 clinical activity to argue that PD-L1 expression marks tumors susceptible to PD-1 pathway blockade.
- cite → Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer — The adaptive immune resistance paper cites early anti-PD-1 trials as clinical evidence that blocking PD-1 can restore antitumor T-cell activity.
- cite ← Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade — The 2017 mismatch-repair paper builds on the mechanism that PD-1 blockade restores antitumor T-cell activity by inhibiting adaptive immune resistance.
- cite ← Pembrolizumab versus Ipilimumab in Advanced Melanoma — The pembrolizumab melanoma trial cites adaptive immune resistance as the PD-1/PD-L1 mechanism explaining checkpoint blockade responses.
- cite ← Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer — The pembrolizumab lung cancer study builds on adaptive immune resistance as the mechanistic rationale for blocking PD-1 signaling in tumors.
- cite ← Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer — The NSCLC PD-1 study cites adaptive immune resistance as the biological mechanism explaining why PD-1 blockade can restore antitumor T-cell activity.